Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
UBS Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $40
Guardant Health Holds 'Underappreciated' Catalyst Path, UBS Says
Bernstein Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $45
Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $42
